A6 P0 — carvacrol/thymol mimics (BIOS not used)
Status: computational / chemical design proposal. Not a measured MIC. Not a drug. Not a KD. BIOS not used on this challenge.
Challenge: A6 / O1 (Lane S — small molecules). Not A2. Not protein binders. Seed: https://x.com/1immortals1/status/2099853239873077575 Pharmacophore freeze: phenolic OH + hydrophobic ring (p-cymene / carvacrol–thymol). Goal: wider bacterial vs host membrane window — not max lipophilicity.
Hard stops: no BIOS run, no Adaptyv order, no dosing or brands, no invented MIC, no “cures MRSA / zero resistance / better than rifaximin.”
Prior art (initial lock; TargetLead P0 table may refine):
- Preuss 2005 (oregano oil / phenolic monoterpenes)
- 2018 MDR / burn oregano oil literature
- 2024 Eur J Med Chem amphipathic thymol/carvacrol series (thy2I lead) — main novelty veto for S2
- 2025 synergy reports vs S. aureus / A. baumannii (to verify in fact-check)
Deliverable this challenge: 12–20 membrane-active analogues (S1 close / S2 amphipathic / S3 adjuvant-hybrid) → Reviewer gate → falsifiable P3/P4 claims with prediction badge.
Single operator; internal review ≠ independent peer review. Falsify-if (preview): any claim that outruns MIC/hemolysis data or invents wet-lab numbers dies.